TITLE

Fentanyl Pectin Nasal Spray: In Breakthrough Pain in Opioid-Tolerant Adults with Cancer

AUTHOR(S)
Lyseng-Williamson, Katherine A.
PUB. DATE
June 2011
SOURCE
CNS Drugs;2011, Vol. 25 Issue 6, p511
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Fentanyl pectin nasal spray (PecFent®) uses a novel pectin-based delivery system that turns from an aqueous solution into a gel when applied to mucosal surfaces. Fentanyl is absorbed in a controlled manner from the pectin gel formed in the nasal cavity, and has a rapid onset of pain relief and duration of action that matches the time course of a typical episode of breakthrough pain in cancer (BTPc). Relative to administration as oral transmucosal fentanyl, fentanyl administered as fentanyl pectin nasal spray is more rapidly absorbed, reaches higher maximum plasma concentrations and has greater bioavailability. In the treatment of BTPc in two randomized, double-blind, crossover trials in opioid-tolerant adults, fentanyl pectin nasal spray (100-800 μg titrated doses) was significantly more effective than placebo in reducing pain intensity and provided a significantly faster onset of pain relief than oral immediate- release morphine. During long-term treatment of BTPc episodes, fentanyl pectin nasal spray consistently provided effective pain relief in an open-label, 16-week trial. Most patients were satisfied or very satisfied with the ease of use and convenience of the nasal spray. Fentanyl pectin nasal spray 100-800 μg was generally well tolerated and was not associated with nasal tolerability problems.
ACCESSION #
64291263

 

Related Articles

  • Is there enough evidence to advocate opioid combinations? Does one and one make two or more? Zylicz, Zbigniew; Mercadante, Sebastiano // Advances in Palliative Medicine;2010, Vol. 9 Issue 2, p31 

    Despite a more than tenfold increase in opioid consumption in the past decades, many cancer patients still suffer pain. The current understanding of this situation is poorly understood. It is still possible that in some countries pain is still undertreated, but it is also possible that we do not...

  • Improved patient functioning after treatment of breakthrough cancer pain: an open-label study of fentanyl buccal tablet in patients with cancer pain. Davies, Andrew; Kleeberg, Ulrich; Jarosz, Jerzy; Mercadante, Sebastiano; Poulain, Philippe; O'Brien, Tony; Schneid, Hélène; Kress, Hans // Supportive Care in Cancer;Jul2015, Vol. 23 Issue 7, p2135 

    Purpose: This open-label study evaluated the effects of fentanyl buccal tablet (FBT) on functioning and mood in cancer patients with breakthrough cancer pain (BTcP). Methods: Opioid-tolerant patients in seven European countries with up to four BTcP episodes/day received FBT doses (100-800 μg)...

  • The Role of Fentanyl in Cancer-Related Pain. Prommer, Eric // Journal of Palliative Medicine;Oct2009, Vol. 12 Issue 10, p947 

    Fentanyl is a lipophilic, short-acting, synthetic opioid with a piperidine chemical structure. Fentanyl is an effective analgesic for cancer pain, and newer formulations such as the transmucosal and buccal forms have shown efficacy for the management of cancer-related breakthrough pain. This...

  • Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial. Shimoyama, Naohito; Gomyo, Ikuo; Katakami, Nobuyuki; Okada, Masakuni; Yukitoshi, Nobuyuki; Ohta, Eri; Shimoyama, Megumi // International Journal of Clinical Oncology;Feb2015, Vol. 20 Issue 1, p198 

    Background: Breakthrough cancer pain typically has a rapid onset and relatively short duration. Due to this temporal profile, it may not be adequately relieved by oral opioid analgesics. The sublingual fentanyl orally disintegrating tablet is a formulation by which fentanyl can be rapidly...

  • Formulation Selection and Pharmacokinetic Comparison of Fentanyl Buccal Soluble Film with Oral Transmucosal Fentanyl Citrate. Vasisht, Niraj; Gever, Larry N.; Tagarro, Ignacio; Finn, Andrew L. // Clinical Drug Investigation;2009, Vol. 29 Issue 10, p647 

    Background and Objectives: BioErodible MucoAdhesive (BEMA®) is a new transmucosal drug delivery system designed to improve and ease the administration of drugs by this route. The first product that uses this novel delivery system contains fentanyl and is intended for the treatment of...

  • Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain. Mercadante, Sebastiano; Vellucci, Renato; Cuomo, Arturo; Adile, Claudio; Cortegiani, Andrea; Valle, Alessandro; Villari, Patrizia; Casuccio, Alessandra // Supportive Care in Cancer;May2015, Vol. 23 Issue 5, p1349 

    Purpose: The aim of the present study was to assess the long-term tolerability and efficacy of intranasal fentanyl (INFS) in opioid-tolerant patients with breakthrough cancer pain (BTP). Patients and methods: A 6 months, observational, prospective, cohort study design was employed to follow...

  • Treating cancer pain: Barriers and fears to overcome. Harman, Stephanie M. // Hem/Onc Today;10/10/2011, Vol. 12 Issue 19, p15 

    The article explores the underuse of opioid medications for cancer pain and the strategies to help patients get the relief they need from cancer pain.

  • Fentanyl.  // AHFS Consumer Medication Information;Aug2019, p1 

    Fentanyl is used to treat breakthrough pain (sudden episodes of pain that occur despite round the clock treatment with pain medication) in cancer patients at least 18 years of age (or at least 16 years of age if taking Actiq brand lozenges) who are taking regularly scheduled doses of another...

  • Intermittent Subcutaneous Opioids for the Management of Cancer Pain. Parsons, Henrique A.; Shukkoor, Abdul; Hue Quan; Delgado-Guay, Marvin O.; Palmer, J. Lynn; Fainsinger, Robin; Bruera, Eduardo // Journal of Palliative Medicine;Dec2008, Vol. 11 Issue 10, p1319 

    The article offers information regarding the proper medical utilization of pain reliever opioids on cancer pain. It tackles intermittent subcutaneous (SC) opioids which is distributed among cancer patients. It also features the medical apparatus, Edmonton Symptom Assessment System (ESAS), used...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics